666 related articles for article (PubMed ID: 28836158)
1. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
[TBL] [Abstract][Full Text] [Related]
3. The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis.
Sun J; Sun H; Cui M; Sun Z; Li W; Wei J; Zhou S
Int Urol Nephrol; 2018 Oct; 50(10):1835-1843. PubMed ID: 29948864
[TBL] [Abstract][Full Text] [Related]
4. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis.
Nochaiwong S; Ruengorn C; Awiphan R; Koyratkoson K; Chaisai C; Noppakun K; Chongruksut W; Thavorn K
Nephrol Dial Transplant; 2018 Feb; 33(2):331-342. PubMed ID: 28339835
[TBL] [Abstract][Full Text] [Related]
5. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
[TBL] [Abstract][Full Text] [Related]
6. Comparing safety of proton-pump inhibitors versus H2-receptor antagonists in kidney transplant recipients: A systematic review and meta-analysis.
Mohammadi K; Yaribash S; Razi B; Dashti-Khavidaki S
J Clin Pharm Ther; 2022 May; 47(5):567-574. PubMed ID: 34931328
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease.
Vengrus CS; Delfino VD; Bignardi PR
Minerva Urol Nephrol; 2021 Aug; 73(4):462-470. PubMed ID: 33769018
[TBL] [Abstract][Full Text] [Related]
8. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
9. The Risks of Incident and Recurrent Clostridium difficile-Associated Diarrhea in Chronic Kidney Disease and End-Stage Kidney Disease Patients: A Systematic Review and Meta-Analysis.
Phatharacharukul P; Thongprayoon C; Cheungpasitporn W; Edmonds PJ; Mahaparn P; Bruminhent J
Dig Dis Sci; 2015 Oct; 60(10):2913-22. PubMed ID: 25986528
[TBL] [Abstract][Full Text] [Related]
10. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis.
Kwok CS; Arthur AK; Anibueze CI; Singh S; Cavallazzi R; Loke YK
Am J Gastroenterol; 2012 Jul; 107(7):1011-9. PubMed ID: 22525304
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: risk of fractures with acid-suppressing medication.
Kwok CS; Yeong JK; Loke YK
Bone; 2011 Apr; 48(4):768-76. PubMed ID: 21185417
[TBL] [Abstract][Full Text] [Related]
12. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
13. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease.
Arora P; Gupta A; Golzy M; Patel N; Carter RL; Jalal K; Lohr JW
BMC Nephrol; 2016 Aug; 17(1):112. PubMed ID: 27487959
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of the effect of acid-suppressant therapy on clinicopathologic parameters of cats with chronic kidney disease.
Gould E; Klos J; Price J; Harris T; Vaden S; Tolbert MK
J Feline Med Surg; 2018 Jun; 20(6):520-527. PubMed ID: 28703633
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: an updated systematic review and network meta-analysis of randomized trials.
Wang Y; Ge L; Ye Z; Siemieniuk RA; Reintam Blaser A; Wang X; Perner A; Møller MH; Alhazzani W; Cook D; Guyatt GH
Intensive Care Med; 2020 Nov; 46(11):1987-2000. PubMed ID: 32833040
[TBL] [Abstract][Full Text] [Related]
17. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.
Klatte DCF; Gasparini A; Xu H; de Deco P; Trevisan M; Johansson ALV; Wettermark B; Ärnlöv J; Janmaat CJ; Lindholm B; Dekker FW; Coresh J; Grams ME; Carrero JJ
Gastroenterology; 2017 Sep; 153(3):702-710. PubMed ID: 28583827
[TBL] [Abstract][Full Text] [Related]
18. Are Proton Pump Inhibitors More Effective Than Histamine-2-Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients? A Systematic Review and Meta-Analysis of Cohort Studies.
He N; Yan Y; Su S; Ge Q; Zhai S
Ann Pharmacother; 2022 Sep; 56(9):988-997. PubMed ID: 34971320
[TBL] [Abstract][Full Text] [Related]
19. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.
Lam JR; Schneider JL; Quesenberry CP; Corley DA
Gastroenterology; 2017 Mar; 152(4):821-829.e1. PubMed ID: 27890768
[TBL] [Abstract][Full Text] [Related]
20. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
